Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
000919.SZ Stock Summary
Top 10 Correlated ETFs
000919.SZ
In the News
000919.SZ Financial details
Company Rating
Buy
Market Cap
3.45B
Income
106.07M
Revenue
2.72B
Book val./share
6.04
Cash/share
2.31
Dividend
0.1
Dividend %
1.28%
Employees
4.88K
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
37.23
Forward P/E
16.32
PEG
-30.81
P/S
1.45
P/B
1.3
P/C
2.9
P/FCF
-20.53
Quick Ratio
2.25
Current Ratio
2.85
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
0.21
EPS next Y
0.41
EPS next Q
-
EPS this Y
-12.5%
EPS next Y
94.31%
EPS next 5Y
94.31%
EPS last 5Y
-15.24%
Revenue last 5Y
-1.63%
Revenue Q/Q
-9.55%
EPS Q/Q
-40.71%
-
-
-
-
SMA20
1.19%
SMA50
-14.57%
SMA100
-14.79%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
3%
ROC
0.03%
Gross Margin
20%
Oper. Margin
5%
Profit Margin
4%
Payout
48%
Shs Outstand
504M
Shs Float
204.66M
-
-
-
-
Target Price
-
52W Range
5.38-10.13
52W High
-33.1%
52W Low
+33.8%
RSI
45.14
Rel Volume
0.38
Avg Volume
8.97M
Volume
3.41M
Perf Week
-4.84%
Perf Month
8.08%
Perf Quarter
-
Perf Half Y
-17.41%
-
-
-
-
Beta
0.488
-
-
Volatility
0.13%, 0.17%
Prev Close
0.3%
Price
6.69
Change
1.67%
000919.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 5.75 | 5.03 | 4.97 | 5.57 | 5.3 | |
Net income per share | 0.48 | 0.29 | 0.19 | 0.24 | 0.21 | |
Operating cash flow per share | 0.86 | 0.92 | 0.62 | 0.58 | 0.52 | |
Free cash flow per share | 0.59 | 0.67 | 0.04 | 0.26 | -0.1 | |
Cash per share | 2.02 | 3.13 | 2.61 | 2.98 | 3.15 | |
Book value per share | 5.43 | 5.71 | 5.67 | 5.81 | 5.94 | |
Tangible book value per share | 5.72 | 6.27 | 6.39 | 6.7 | 6.63 | |
Share holders equity per share | 5.43 | 5.71 | 5.67 | 5.81 | 5.94 | |
Interest debt per share | 0.01 | 0.06 | 0.08 | 0.03 | 0.01 | |
Market cap | 3.1B | 3.68B | 3.88B | 3.86B | 3.92B | |
Enterprise value | 2.14B | 2.25B | 2.6B | 2.37B | 2.43B | |
P/E ratio | 12.84 | 25.32 | 41.38 | 31.96 | 37.19 | |
Price to sales ratio | 1.07 | 1.45 | 1.55 | 1.37 | 1.47 | |
POCF ratio | 7.16 | 7.9 | 12.44 | 13.2 | 15.03 | |
PFCF ratio | 10.44 | 10.82 | 193.24 | 29.83 | -79.83 | |
P/B Ratio | 1.13 | 1.28 | 1.36 | 1.32 | 1.31 | |
PTB ratio | 1.13 | 1.28 | 1.36 | 1.32 | 1.31 | |
EV to sales | 0.74 | 0.89 | 1.04 | 0.84 | 0.91 | |
Enterprise value over EBITDA | 4.41 | 4.85 | 8.66 | 7.58 | 11.08 | |
EV to operating cash flow | 4.93 | 4.82 | 8.35 | 8.12 | 9.31 | |
EV to free cash flow | 7.19 | 6.6 | 129.63 | 18.34 | -49.46 | |
Earnings yield | 0.08 | 0.04 | 0.02 | 0.03 | 0.03 | |
Free cash flow yield | 0.1 | 0.09 | 0.01 | 0.03 | -0.01 | |
Debt to equity | 0 | 0.01 | 0.01 | 0.01 | 0 | |
Debt to assets | 0 | 0.01 | 0.01 | 0 | 0 | |
Net debt to EBITDA | -1.99 | -3.1 | -4.25 | -4.75 | -6.8 | |
Current ratio | 3.7 | 3.32 | 2.56 | 2.67 | 3.04 | |
Interest coverage | 137.31 | 798.72 | 470.25 | 673.8 | 370.18 | |
Income quality | 1.5 | 2.54 | 3.33 | 1.91 | 2.29 | |
Dividend Yield | 0.04 | 0.02 | 0.02 | 0.01 | 0.01 | |
Payout ratio | 0.53 | 0.59 | 0.96 | 0.42 | 0.49 | |
Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
Research and developement to revenue | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 | |
Intangibles to total assets | 0.09 | 0.06 | 0.05 | 0.04 | 0.06 | |
Capex to operating cash flow | -0.31 | -0.27 | -0.94 | -0.56 | -1.19 | |
Capex to revenue | -0.05 | -0.05 | -0.12 | -0.06 | -0.12 | |
Capex to depreciation | -1.11 | -1.03 | -2.43 | -1.32 | -2.49 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.01 | |
Graham number | 7.66 | 6.09 | 4.87 | 5.59 | 5.28 | |
ROIC | 0.11 | 0.09 | 0.05 | 0.05 | 0.03 | |
Return on tangible assets | 0.07 | 0.04 | 0.02 | 0.03 | 0.02 | |
Graham Net | 1.85 | 2.54 | 1.89 | 2.21 | 2.35 | |
Working capital | 1.64B | 1.57B | 1.25B | 1.43B | 1.77B | |
Tangible asset value | 2.88B | 3.16B | 3.22B | 3.38B | 3.34B | |
Net current asset value | 1.61B | 1.51B | 1.2B | 1.38B | 1.72B | |
Invested capital | 0 | 0.01 | 0.01 | 0.01 | 0 | |
Average receivables | 634.95M | 506.01M | 467.23M | 520.32M | 525.84M | |
Average payables | 287.67M | 288.45M | 401.03M | 472.57M | 466.7M | |
Average inventory | 326.52M | 235.26M | 224.71M | 230.46M | 247.98M | |
Days sales outstanding | 73.23 | 61.97 | 73.49 | 69.72 | 70.39 | |
Days payables outstanding | 39.87 | 63.38 | 87.53 | 80.31 | 77.34 | |
Days of inventory on hand | 39.2 | 44.1 | 40.48 | 41.13 | 42.67 | |
Receivables turnover | 4.98 | 5.89 | 4.97 | 5.23 | 5.19 | |
Payables turnover | 9.15 | 5.76 | 4.17 | 4.54 | 4.72 | |
Inventory turnover | 9.31 | 8.28 | 9.02 | 8.88 | 8.55 | |
ROE | 0.09 | 0.05 | 0.03 | 0.04 | 0.04 | |
Capex per share | -0.27 | -0.25 | -0.58 | -0.32 | -0.61 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.38 | 1.26 | 1.41 | 1.45 | 1.32 | |
Net income per share | 0.07 | 0.02 | 0.09 | 0.07 | 0.04 | |
Operating cash flow per share | 0.07 | 0.02 | 0.09 | 0.06 | -0.03 | |
Free cash flow per share | 0.01 | -0.21 | 0 | -0.02 | -0.16 | |
Cash per share | 3 | 3.25 | 3.02 | 3 | 2.31 | |
Book value per share | 5.89 | 6.12 | 6.03 | 6.1 | 6.04 | |
Tangible book value per share | 6.59 | 6.83 | 6.73 | 6.81 | 6.75 | |
Share holders equity per share | 5.89 | 6.12 | 6.03 | 6.1 | 6.04 | |
Interest debt per share | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
Market cap | 3.43B | 3.8B | 3.91B | 3.94B | 4.15B | |
Enterprise value | 2.29B | 2.31B | 2.65B | 2.7B | 3.24B | |
P/E ratio | 25.45 | 112.25 | 22.43 | 29.05 | 51.65 | |
Price to sales ratio | 4.89 | 6.16 | 5.52 | 5.38 | 6.26 | |
POCF ratio | 101.8 | 449.01 | 89.71 | 125.06 | -305.63 | |
PFCF ratio | 1.02K | -36.64 | 2.52K | -323.96 | -53.1 | |
P/B Ratio | 1.14 | 1.27 | 1.29 | 1.28 | 1.36 | |
PTB ratio | 1.14 | 1.27 | 1.29 | 1.28 | 1.36 | |
EV to sales | 3.27 | 3.74 | 3.75 | 3.68 | 4.89 | |
Enterprise value over EBITDA | 81.2 | -73.33 | 44.55 | 60.63 | 120.5 | |
EV to operating cash flow | 68.03 | 272.92 | 60.9 | 85.58 | -238.76 | |
EV to free cash flow | 681.3 | -22.27 | 1.71K | -221.68 | -41.48 | |
Earnings yield | 0.01 | 0 | 0.01 | 0.01 | 0 | |
Free cash flow yield | 0 | -0.03 | 0 | 0 | -0.02 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | -40.31 | 47.31 | -21.07 | -27.97 | -33.75 | |
Current ratio | 2.8 | 3.04 | 3.27 | 3.36 | 2.85 | |
Interest coverage | 830.21 | 27.34 | 4.52K | 470.12 | 552.55 | |
Income quality | 1 | 1 | 1 | 0.93 | -0.68 | |
Dividend Yield | 0.01 | 0 | 0 | 0 | 0.01 | |
Payout ratio | 1.51 | 0 | 0 | 0.02 | 2.51 | |
Sales general and administrative to revenue | 0.27 | -0.24 | 0.11 | -0.05 | 0.3 | |
Research and developement to revenue | 0.04 | 0.05 | 0.02 | 0.02 | 0.02 | |
Intangibles to total assets | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | |
Capex to operating cash flow | -0.9 | -13.26 | -0.96 | -1.39 | 4.76 | |
Capex to revenue | -0.04 | -0.18 | -0.06 | -0.06 | -0.1 | |
Capex to depreciation | -0.85 | -3.14 | -1.24 | -1.28 | 1.02 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 2.96 | 1.54 | 3.43 | 3.04 | 2.33 | |
ROIC | 0.01 | 0.03 | 0.02 | 0.01 | 0.01 | |
Return on tangible assets | 0.01 | 0 | 0.01 | 0.01 | 0 | |
Graham Net | 2.37 | 2.42 | 2.44 | 2.51 | 1.86 | |
Working capital | 1.54B | 1.77B | 1.82B | 1.88B | 1.5B | |
Tangible asset value | 3.36B | 3.34B | 3.39B | 3.43B | 3.4B | |
Net current asset value | 1.49B | 1.72B | 1.77B | 1.83B | 1.46B | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 633.03M | 573.13M | 547.12M | 610.97M | 657.88M | |
Average payables | 452.99M | 459.44M | 451.56M | 438.64M | 438.2M | |
Average inventory | 225.3M | 238.69M | 240.65M | 233.85M | 248.98M | |
Days sales outstanding | 80.95 | 75.13 | 73.56 | 78.94 | 91.37 | |
Days payables outstanding | 75.11 | 77.99 | 72.26 | 67.65 | 76.69 | |
Days of inventory on hand | 36.66 | 43.03 | 37.14 | 37.43 | 44.67 | |
Receivables turnover | 1.11 | 1.2 | 1.22 | 1.14 | 0.99 | |
Payables turnover | 1.2 | 1.15 | 1.25 | 1.33 | 1.17 | |
Inventory turnover | 2.45 | 2.09 | 2.42 | 2.4 | 2.01 | |
ROE | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
Capex per share | -0.06 | -0.23 | -0.08 | -0.09 | -0.13 |
000919.SZ Frequently Asked Questions
What is Jinling Pharmaceutical Company Limited stock symbol ?
Jinling Pharmaceutical Company Limited is a CN stock and trading under the symbol 000919.SZ
What is Jinling Pharmaceutical Company Limited stock quote today ?
Jinling Pharmaceutical Company Limited stock price is $6.69 today.
Is Jinling Pharmaceutical Company Limited stock public?
Yes, Jinling Pharmaceutical Company Limited is a publicly traded company.